Cellectar Biosciences, Inc.

CLRB

Explore Our Financial Data > Companies > Cellectar Biosciences, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
CLRB
CIK0001279704
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
Website cellectar.com
Phone(608) 441-8120
CEOJames V. Caruso
Employees10

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-24.48 million
Net Income$-24.54 million
Net Income to Common$-24.54 million
EPS$-0.53
View All
Balance Sheet
Cash$13.91 million
Assets$16.04 million
Liabilities$6.41 million
Common Equity$7.73 million
Liabilities & Equity$16.04 million
View All
Cash Flow Statement
Net Income$-24.54 million
Cash From Operating Activities$-43.60 million
Cash From Investing Activities$-82,562.00
Cash From Financing Activities$17.56 million
Change in Cash$-26.13 million
View All
Calculations
NOPAT$-32.32 million
EBITDA$-25.25 million
Price to EarningsN/A
Price to Book$2.18
ROE-208.72%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 MedianFLORHAM PARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced initial results as of June 10, 2025, from the CLOVER-2 Phase 1 clinical trial evaluating iopofosine I 131 in relapsed/refractory pediatric high-

Article Link

Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

Article Link

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million from the sale of shares of the company’s common stock priced at-market for Nasdaq purposes. The closing of the offering is expected to occur on or about June 6, 2025, subject to satisfaction of custom

Article Link

What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained

Cellectar Biosciences, Inc. (NASDAQ:CLRB) stock is trading higher on Wednesday. As per data from Benzinga Pro, session volume stands at 361.96 million versus an average volume of 968.03k. What Happened: The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation on Wednesday for the company’s iopofosine I 131, a potential first-in-class, novel cancer-targeting agent utilizing a phospholipid ether as a radioconjugate monotherapy, for relapsed/refractory Waldenstrom macrog

Article Link

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Designation Supported by CLOVER WaM Phase 2 Study DataWhich Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, Answer Expected Late July FLORHAM PARK, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer,

Article Link